Autosomal Recessive Hyperinsulinemic Hypoglycemia Due to SUR1 Deficiency

Autosomal recessive hyperinsulinemic hypoglycemia due to SUR1 deficiency is a rare, inherited condition in which a baby or child has too much insulin in the blood even when blood sugar is low. The extra insulin drives glucose out of the bloodstream, so the child becomes hypoglycemic (low blood sugar). If hypoglycemia is severe or lasts a long time, it can cause seizures or brain injury; if it is recognized early and treated well, children can do very well. The medical name for this group of disorders is congenital hyperinsulinism (CHI). In the SUR1 form, the problem comes from harmful variants (“mutations”) in a gene called ABCC8, which makes the SUR1 protein. SUR1 is one half of a tiny potassium channel (KATP channel) on the surface of pancreatic beta cells; that channel acts like an off-switch for insulin release. When SUR1 is missing or broken, the channel does not work, the cell thinks sugar is always high, and insulin is released inappropriately, causing low blood glucose. This SUR1 form is often autosomal recessive, meaning a child inherits one non-working ABCC8 copy from each parent. Many—but not all—children with recessive SUR1 disease are not responsive to diazoxide, the usual first-line medicine for CHI. Medscape+3NCBI+3MedlinePlus+3

Autosomal recessive hyperinsulinemic hypoglycemia due to SUR1 deficiency is a genetic disorder in which the beta cells of the pancreas release too much insulin even when blood sugar is low. It happens because both copies of the ABCC8 gene, which makes the SUR1 subunit of the K_ATP channel, are faulty. When SUR1 does not work, the K_ATP channel stays closed. That makes the beta cell stay “on,” pushing insulin out all the time. The result is frequent or persistent low blood sugar in newborns and infants, which can hurt the brain if not treated quickly. Many babies with biallelic ABCC8 variants do not respond to diazoxide, the usual first medicine, so they often need other treatments or surgery. The clinical goal is to keep glucose ≥70 mg/dL to protect the brain. NCBI+1

Why “SUR1 deficiency”? The SUR1 protein (encoded by ABCC8) forms the regulatory subunit of the KATP channel with Kir6.2 (encoded by KCNJ11). Variants that prevent SUR1 from reaching the cell surface or from opening the channel cause continuous insulin release. PMC

---

Other names

• Congenital hyperinsulinism (CHI) / hyperinsulinemic hypoglycemia (HH)

• ABCC8-related CHI / SUR1-related CHI

• Persistent hyperinsulinemic hypoglycemia of infancy (PHHI) (older term)

• Diazoxide-unresponsive CHI (describes many recessive SUR1 cases)

• KATP-HI (KATP-channel hyperinsulinism)

• Familial hyperinsulinism (when inherited) NCBI+2Orpha+2

---

Types

Even within ABCC8/SUR1 deficiency, doctors see patterns that matter for testing and treatment:

1. Diffuse disease (usually autosomal recessive)
   Both ABCC8 copies are non-working in all beta cells. Hypoglycemia is often severe from the newborn period and typically does not respond to diazoxide. PMC+1

2. Focal disease (paternal ABCC8 variant + maternal 11p15 loss in a small area)
   Only a patch of the pancreas makes too much insulin; a special scan can localize the spot and curative surgery can be possible. (Note: focal disease classically involves a paternally inherited variant; the overall mechanism is still KATP channel failure.) jcrpe.org+1

3. Diazoxide-unresponsive vs diazoxide-responsive
   Most recessive SUR1 cases are unresponsive because the channels never reach or open at the membrane; some dominant SUR1 variants can be milder and diazoxide-sensitive. Your clinician will test responsiveness early. PMC+1

4. Age at onset
   Classic onset is within hours to days after birth, but milder ABCC8 variants can present later in infancy or childhood with feeding difficulty, irritability, or seizures during illness or fasting. NCBI

5. Molecular mechanism subtypes

   • Trafficking defects (SUR1 never reaches the surface; often severe)

   • Gating defects (channel reaches the surface but will not open)

   • Large deletions/duplications in ABCC8
     These mechanisms shape drug response and, in research settings, may be rescuable by “pharmacochaperones.” PubMed+1

---

Causes

The root cause is ABCC8 (SUR1) loss-of-function; the items below explain how genetics and real-life stressors combine to trigger hypoglycemia in a child who has SUR1 deficiency.

1. Biallelic (recessive) ABCC8 pathogenic variants that abolish channel function (missense, nonsense, frameshift, splice). NCBI

2. Compound heterozygosity (two different damaging ABCC8 variants, one from each parent). ScienceDirect

3. ABCC8 deletions/duplications causing loss of SUR1 protein. PubMed

4. Trafficking-defect variants in SUR1 TMD0/L0 that keep KATP channels from reaching the cell surface. PubMed

5. Gating-defect variants that keep the channel closed even when ATP/ADP signals say it should open. PMC

6. Focal pancreatic lesion (paternal ABCC8 variant + somatic maternal 11p loss), making a “hot spot” of insulin secretion. jcrpe.org

7. Perinatal stressors (prolonged fasting between feeds) that lower glucose and unmask the insulin excess. Karger Publishers

8. Intercurrent infection/fever, which increases glucose use and can precipitate hypoglycemia. Karger Publishers

9. Poor oral intake or vomiting from any cause. National Organization for Rare Disorders

10. Cold stress in newborns (higher energy needs). National Organization for Rare Disorders

11. Inadequate night feeds or prolonged sleep without feeds in infants. National Organization for Rare Disorders

12. Strenuous exercise in older children without planned carbohydrate intake. Karger Publishers

13. Post-operative fasting without glucose support. Karger Publishers

14. Medication interruptions (e.g., diazoxide or octreotide held or doses missed in those who respond). Karger Publishers

15. Malabsorption/diarrhea, reducing carbohydrate availability. Karger Publishers

16. High-protein load (some children with CHI are sensitive; rapid insulin rise can follow a protein-heavy meal). jcrpe.org

17. Rapid IV insulin or insulin-sensitizing states (rare, but can aggravate in hospital settings). Karger Publishers

18. Growth spurts (higher energy need, longer gaps). Karger Publishers

19. Prematurity/low birth weight (less glycogen reserve). National Organization for Rare Disorders

20. Dehydration or poor perfusion during illness, increasing stress and glucose use. Karger Publishers

---

Common symptoms and signs

1. Jitteriness or tremor—the first visible sign of low sugar in newborns and infants. NCBI

2. Poor feeding or refusing feeds; weak suck. NCBI

3. Irritability or unusual fussiness that improves with feeding/glucose. National Organization for Rare Disorders

4. Lethargy, sleepiness, or floppy tone (hypotonia). NCBI

5. Sweating, pallor, or rapid heartbeat (adrenergic signs of hypoglycemia). Karger Publishers

6. Apnea or breathing pauses in neonates during severe lows. NCBI

7. Seizures—often the presenting emergency. NCBI

8. Low body temperature (hypothermia) in newborns with persistent hypoglycemia. National Organization for Rare Disorders

9. Cyanosis or dusky color during profound hypoglycemia events. Karger Publishers

10. Poor weight gain if feeds are difficult or frequent IV glucose is needed. National Organization for Rare Disorders

11. Developmental delay if hypoglycemia is frequent or prolonged before diagnosis. Karger Publishers

12. Macroglossia or large birth weight is not typical for SUR1 alone but can coexist in syndromic forms; SUR1 deficiency itself mainly causes hypoglycemia. (Distinguishes ABCC8 from other causes.) National Organization for Rare Disorders

13. Behavior changes in toddlers/children (tantrums, confusion) before meals. Karger Publishers

14. Nausea or vomiting when glucose is low. Karger Publishers

15. Headache in older children signaling an oncoming low. Karger Publishers

---

Diagnostic tests

A) Physical exam (at the bedside)

1. General newborn/child check
   The clinician looks for signs of low sugar: jitteriness, sweating, pallor, limp tone, poor feeding, or seizures. Vital signs (heart rate, breathing, temperature) and hydration are recorded. This helps decide if immediate glucose is needed while tests are drawn. NCBI

2. Neurologic exam
   Reflexes, tone, level of alertness, and seizure activity are assessed. Repeated severe hypoglycemia can affect brain function, so the exam helps judge urgency and need for EEG/brain imaging if seizures occur. Karger Publishers

3. Growth and nutrition review
   Weight, length/height, head circumference, and feeding pattern tell the team about energy needs, fasting tolerance, and whether frequent lows have affected growth—clues that point to CHI if other causes are unlikely. National Organization for Rare Disorders

4. Signs of other disorders
   The doctor looks for features suggesting alternative diagnoses (liver disease, endocrine deficiencies, or syndromes). Lack of these features supports a primary pancreatic cause such as SUR1 deficiency. Karger Publishers

B) Manual/functional tests (dynamic bedside testing)

5. Bedside glucose monitoring (fingerstick + confirmatory lab)
   During symptoms, a quick check confirms hypoglycemia. A laboratory plasma glucose is then drawn for accuracy and for the “critical sample” (see below). CHI is suspected when glucose is low but insulin is still being secreted. Karger Publishers

6. Supervised fasting study (in hospital)
   A carefully monitored fast (with IV access) observes how quickly hypoglycemia occurs and allows timed “critical samples.” In CHI, glucose falls faster than expected, ketones stay low, and insulin remains inappropriately present. The study stops the moment thresholds are met for safety. Karger Publishers

7. Glucagon stimulation test
   When glucose drops, a small glucagon dose is given. If blood sugar rises strongly, it means insulin had been driving glucose into tissues and liver stores were blocked—pattern supportive of CHI. jcrpe.org

8. Trial of diazoxide (when appropriate)
   A short, closely monitored medication trial helps sort diazoxide-responsive vs unresponsive disease. Recessive SUR1 cases are usually unresponsive; lack of response steers clinicians toward octreotide and imaging for focal lesions. PMC

C) Laboratory & pathological tests (“critical sample” and genetics)

9. Critical sample during hypoglycemia
   At the time plasma glucose is low (often ≤50–55 mg/dL), blood is drawn for: insulin, C-peptide, beta-hydroxybutyrate (ketones), free fatty acids, lactate, cortisol, growth hormone, ammonia, and sometimes acylcarnitine profile. In CHI, insulin/C-peptide are inappropriately detectable, ketones/FFAs are suppressed, and glucose may rise after glucagon. Karger Publishers

10. Basic metabolic panel
    Electrolytes, bicarbonate, and liver enzymes help rule out metabolic diseases and guide safe glucose/fluids. Karger Publishers

11. Genetic testing for ABCC8 (and KCNJ11)
    Sequencing and deletion/duplication testing confirm ABCC8 variants; results guide treatment (expect diazoxide-unresponsive disease in many recessive SUR1 cases) and family counseling. Testing may also include a CHI panel. NCBI+1

12. Parental testing & segregation analysis
    Finding one pathogenic variant in each parent supports autosomal recessive inheritance. In suspected focal disease, demonstrating a paternally inherited variant can change surgical planning. jcrpe.org

13. Pancreatic pathology (when surgery occurs)
    If focal disease is removed, pathology confirms a focal adenomatous hyperplasia; diffuse disease shows beta-cell hyperfunction throughout the resected tissue. This is not a first-line test; it follows imaging and surgical decisions. jcrpe.org

D) Electrodiagnostic tests

14. Electroencephalogram (EEG)
    Used if the child has seizures or unexplained spells. EEG looks for seizure activity caused by low glucose and helps guide anti-seizure care while glucose is stabilized. The EEG itself does not diagnose CHI, but it documents brain effects of hypoglycemia. Karger Publishers

15. Electrocardiogram (ECG)
    Severe hypoglycemia can stress the heart; an ECG is simple and quick if episodes are severe or if medications like octreotide are being started. Again, this supports safe care rather than diagnosing CHI directly. Karger Publishers

E) Imaging tests

16. 18F-DOPA PET/CT (or PET/MRI) of the pancreas
    This specialized scan is the key imaging test to distinguish focal from diffuse disease because focal lesions take up tracer intensely. Identifying a focal hotspot can allow limited surgery that cures the condition. jcrpe.org

17. Pancreatic MRI
    MRI can show the pancreas but is less sensitive than 18F-DOPA PET for focal lesions; it is sometimes used when PET is unavailable or to plan surgery. jcrpe.org

18. Ultrasound (abdominal)
    Often normal in CHI; may be used to exclude other abdominal pathology in an infant with vomiting or persistent illness. jcrpe.org

19. Brain MRI (if neurologic concerns)
    If seizures were prolonged or development lags after severe hypoglycemia, MRI checks for injury and guides therapies. This is about consequences, not the pancreatic cause. Karger Publishers

20. Continuous glucose monitoring (CGM)
    In some centers, CGM helps visualize patterns, catch silent overnight lows, and titrate feeds/medicines. It complements, but doesn’t replace, laboratory diagnosis. edm.bioscientifica.com

Non-pharmacological treatments

1. Frequent, scheduled feeds
   What/why: Give breast milk or formula more often (including overnight) to avoid long gaps. Purpose: Prevent dips in glucose by steady intake. Mechanism: Regular carbohydrate entry keeps hepatic glucose output up and counters insulin’s lowering effect. Evidence note: Standard first-line supportive care in guidelines for persistent neonatal hypoglycemia/CHI. Pediatric Endocrine Society

2. Concentrated formula under specialist guidance
   What/why: Temporarily increase caloric density if total volume is limited. Purpose: Deliver more carbs per mL when infants cannot take large volumes. Mechanism: Raises exogenous glucose supply to offset insulin-driven uptake. Evidence: Pediatric Endocrine Society (PES) guidance emphasizes maintaining adequate glucose delivery. Pediatric Endocrine Society

3. Continuous enteral feeding via NG/G-tube (including overnight)
   What/why: Use feeding tube for continuous glucose delivery in severe cases. Purpose: Smooth glucose profile and avoid fasting. Mechanism: Constant carbohydrate flow stabilizes plasma glucose despite inappropriate insulin. Evidence: Recommended supportive strategy in persistent hypoglycemia disorders/CHI pathways. Pediatric Endocrine Society

4. Avoidance of prolonged fasting
   What/why: Keep maximum safe fasting times short; wake for feeds. Purpose: Prevent hypoglycemic episodes. Mechanism: Limits reliance on endogenous glucose production, which insulin suppresses in CHI. Evidence: Core prevention principle across neonatal hypoglycemia guidance. Pediatric Endocrine Society

5. Immediate treatment of intercurrent illness
   What/why: Fever/illness increases glucose needs. Purpose: Earlier feeds and monitoring during illness to avert crashes. Mechanism: Counters stress-related swings and reduced intake. Evidence: Common recommendation within CHI care plans and PES statements. Pediatric Endocrine Society

6. Home glucose monitoring & caregiver training
   What/why: Teach parents to check glucose and give rescue therapy. Purpose: Detect lows early and treat fast. Mechanism: Data-driven feeding and rescue glucagon use reduce neuroglycopenia risk. Evidence: Endocrine recommendations stress education and monitoring in persistent hypoglycemia. Pediatric Endocrine Society

7. Buccal 40% dextrose gel for mild/moderate episodes (per local protocol)
   What/why: Rub gel inside cheek during mild to moderate hypoglycemia when able to feed. Purpose: Quick, non-invasive rescue to raise glucose. Mechanism: Rapid mucosal glucose absorption plus subsequent feeding. Evidence: Randomized Sugar Babies trial showed dextrose gel improves reversal of neonatal hypoglycemia vs feeding alone. (Use per hospital protocol in CHI.) PubMed+1

8. IV dextrose infusion in acute severe hypoglycemia
   What/why: Hospital IV glucose to promptly correct symptomatic/severe lows. Purpose: Neuroprotection during crises. Mechanism: Immediate glucose delivery bypassing GI tract. Evidence: Standard of care for symptomatic neonatal hypoglycemia/CHI flares in guideline pathways. Pediatric Endocrine Society

9. 18F-DOPA PET/CT localization before surgery
   What/why: Advanced imaging to map focal lesions. Purpose: Plan curative limited resection when focal CHI is suspected. Mechanism: Beta-cell uptake of radiolabeled DOPA highlights hyperfunctioning focus. Evidence: Systematic studies show superior accuracy vs older invasive localization methods. PMC+1

10. Early genetic testing (ABCC8/KCNJ11 panel)
    What/why: Confirm molecular diagnosis; inform therapy choice (e.g., diazoxide response unlikely with biallelic KATP variants). Purpose: Personalize care and anticipate surgical needs. Mechanism: Genotype–phenotype correlation guides decision-making. Evidence: GeneReviews and pediatric endocrine guidance recommend early testing in persistent hypoglycemia. NCBI+1

11. Dietitian-led feeding plan with slow-release carbohydrate at night (selected cases)
    What/why: Consider supervised addition of slow-release starch (in older infants/children) to support nocturnal glucose. Purpose: Reduce nighttime dips between feeds. Mechanism: Slow digestion extends glucose availability. Evidence: Data for uncooked cornstarch come mainly from diabetes/GSD contexts; may be selectively applied with specialist oversight. PubMed+1

12. Emergency action plan (written)
    What/why: Clear steps for caregivers: monitor, feed, gel, glucagon, call EMS. Purpose: Standardized rapid response. Mechanism: Reduces treatment delay and variability. Evidence: Aligns with persistent hypoglycemia safety practices endorsed by PES/center protocols. Pediatric Endocrine Society

13. Temperature control and stress minimization
    What/why: Keep infant warm and calm. Purpose: Limit extra glucose use during cold stress or agitation. Mechanism: Reduces catecholamine-driven swings that complicate lows in CHI. Evidence: General neonatal hypoglycemia management principles. Pediatric Endocrine Society

14. Structured illness “sick-day” feeding plan
    What/why: Higher-frequency feeds and earlier intervention with gel/IV during illness. Purpose: Prevent admissions and severe lows. Mechanism: Anticipatory carbohydrate support. Evidence: Persistent hypoglycemia management frameworks recommend proactive adjustments during illness. Pediatric Endocrine Society

15. Neurodevelopmental follow-up
    What/why: Early therapy services if delays are suspected. Purpose: Address possible sequelae of early hypoglycemia. Mechanism: Early intervention improves developmental outcomes. Evidence: Standard recommendation in CHI cohorts with brain-risk history. PMC

16. Inpatient multidisciplinary pathway (endocrine + surgery + genetics + dietetics)
    What/why: Centralized CHI pathway in tertiary center. Purpose: Faster diagnosis, optimized therapy, fewer complications. Mechanism: Coordinated care and rapid imaging/testing. Evidence: Reflected in contemporary reviews and PES recommendations. Pediatric Endocrine Society+1

17. Caregiver CPR and seizure-response training
    What/why: Prepare families to respond to severe events while awaiting EMS. Purpose: Safety net for rare emergencies. Mechanism: Prevents prolonged hypoglycemia injury. Evidence: General pediatric safety guidance in high-risk metabolic disorders. Pediatric Endocrine Society

18. Hospital glucose protocols for procedures
    What/why: Glucose infusions during anesthesia/fasting for scans or surgery. Purpose: Avoid peri-procedural lows. Mechanism: Continuous parenteral carbohydrate delivery. Evidence: Standard peri-operative care in CHI programs. Pediatric Endocrine Society

19. Parent support and registry enrollment
    What/why: Connect with CHI centers/registries. Purpose: Access to specialized advice and emerging options. Mechanism: Shared data improve care pathways. Evidence: Emphasized in reviews of rare disease care models. PMC

20. Regular medication side-effect screening
    What/why: Watch for edema (diazoxide), gallstones and glucose changes (somatostatin analogs), immunosuppression risks (mTOR inhibitors). Purpose: Keep therapy safe. Mechanism: Early detection and dose adjustment. Evidence: Summarized in FDA labels and endocrine guidance. FDA Access Data+2FDA Access Data+2

---

Drug treatments

⚠️ Important: Many drugs below are off-label for CHI. Dosing must be individualized by a pediatric endocrinologist. I cite FDA labels (accessdata.fda.gov) for class/mechanism/safety where available and note when CHI use is off-label.

1. Diazoxide (PROGLYCEM®) — K_ATP channel opener
   Class/Mechanism: Nondiuretic benzothiadiazine; inhibits insulin release by opening pancreatic K_ATP channels. Use in CHI: First-line in many forms of HI, but biallelic ABCC8/KCNJ11 forms are commonly diazoxide-unresponsive. Typical dose range: Label provides oral suspension 50 mg/mL; pediatric dosing individualized (specialist dosing). Purpose: Raise glucose by reducing insulin secretion. Key adverse effects: Fluid retention/edema, hypertrichosis, GI upset; monitor for pulmonary hypertension in neonates. Evidence: FDA label; GeneReviews on poor response in biallelic KATP variants. FDA Access Data+1

2. Octreotide (Sandostatin®) — Somatostatin analog (off-label for CHI)
   Class/Mechanism: Binds somatostatin receptors, suppresses insulin release. Use: Second-line for diazoxide-unresponsive CHI. Typical regimen: Short-acting SC/IV multiple times daily; conversion to LAR in selected older children under specialty care. Purpose: Blunt inappropriate insulin secretion. Key adverse effects: GI cramps, gallstones, potential effects on glucose tolerance. Evidence: FDA label; pediatric CHI reviews endorse as second-line. FDA Access Data+1

3. Lanreotide (Somatuline® Depot) — Long-acting somatostatin analog (off-label)
   Class/Mechanism: Long-acting SSTR agonist; reduces insulin release. Use: Alternative to octreotide in selected CHI patients. Typical dosing: 60–120 mg deep SC every 4 weeks (per label for approved indications; CHI dosing is specialist-directed). Side effects: Similar to octreotide (GI, gallstones), injection-site pain. Evidence: FDA label notes class effects; CHI series report benefit in diazoxide-unresponsive cases. FDA Access Data+1

4. Glucagon (for injection) — Counter-regulatory hormone (rescue use)
   Class/Mechanism: Stimulates hepatic glycogen breakdown to raise blood glucose. Use: Emergency treatment for severe hypoglycemia and as short-term infusion bridge. Typical dosing: Label provides SC/IM/IV dosing for severe hypoglycemia; continuous IV infusion sometimes used in hospital (off-label). Adverse effects: Nausea, vomiting; requires hepatic glycogen stores. Evidence: FDA labels. FDA Access Data+1

5. Sirolimus (Rapamune®) — mTOR inhibitor (off-label)
   Class/Mechanism: Inhibits mTOR pathway; in CHI may reduce beta-cell hyperfunction in refractory cases. Use: Case-by-case when diazoxide/somatostatin fail and surgery is not feasible. Typical dosing: Specialist-directed with trough monitoring; label dosing is for transplant indications. Adverse effects: Immunosuppression, infection risk, mouth ulcers, hyperlipidemia. Evidence: FDA label for safety/PK; limited CHI case series. FDA Access Data+1

6. Everolimus (Afinitor®) — mTOR inhibitor (off-label)
   Class/Mechanism: mTOR inhibition; decreases insulin secretion/proliferation signals. Use: Selected refractory CHI similar to sirolimus when benefits outweigh risks. Typical dosing: Specialist-directed; label dosing is for oncology/TSC. Adverse effects: Stomatitis, infections, hyperglycemia, dyslipidemia. Evidence: FDA labels. FDA Access Data+1

7. Nifedipine (Procardia®/Procardia XL®) — Calcium-channel blocker (off-label, limited efficacy)
   Class/Mechanism: L-type Ca²⁺ channel blocker; may reduce insulin exocytosis in some cases. Use: Historically tried; evidence inconsistent, often insufficient benefit in CHI. Dose: Label dosing is for hypertension/angina, not CHI; any use is specialist-directed. Adverse effects: Hypotension, flushing, edema. Evidence: FDA labels; mixed reports in CHI literature. FDA Access Data+1

8. Pasireotide (Signifor® / Signifor LAR®) — Broad-spectrum somatostatin analog (off-label)
   Class/Mechanism: High affinity SSTR5 agonist; potent suppression of islet hormones. Use: Experimental in CHI where other agents fail. Dose: Label regimens exist for Cushing’s/acromegaly; CHI use is specialist-guided. Adverse effects: Hyperglycemia can be significant, plus GI and gallbladder effects—requires careful balance in CHI. Evidence: FDA labels highlight hyperglycemia risk. FDA Access Data+1

9. Hydrochlorothiazide (adjunct to diazoxide-induced edema) (off-label adjunct)
   Class/Mechanism: Thiazide diuretic; treats fluid retention caused by diazoxide. Use: Supportive when edema limits diazoxide therapy. Adverse effects: Electrolyte shifts; monitor closely. Evidence: Practice described in CHI management reviews; diuretic class labeling provides safety context. PMC

10. Continuous IV dextrose (various concentrations) (acute hospital therapy)
    Class/Mechanism: Parenteral carbohydrate; directly raises plasma glucose. Use: Acute stabilization, peri-operative support. Adverse effects: Line complications; hyperglycemia if overshoot. Evidence: Standard of care per PES guidance for persistent hypoglycemia. Pediatric Endocrine Society

11. Glucose 40% buccal gel (see also Non-pharm #7)
    Mechanism/Use: Rapid mucosal absorption for mild to moderate events alongside feeds. Adverse effects: Minimal; ensure safe swallowing. Evidence: RCT shows benefit in neonatal hypoglycemia. PubMed

12. (Reserved) Specialized combinations in ICU (glucose ± glucagon infusion)
    Use: Stabilize severe CHI while imaging/genetics completed. Evidence: Hospital pathway practice and PES principles. Pediatric Endocrine Society

Note: Truly FDA-approved, on-label therapy for hypoglycemia due to hyperinsulinism is diazoxide; others here are used off-label in CHI based on mechanism and clinical experience. Genetic form (ABCC8 biallelic) is often diazoxide-unresponsive, which is why somatostatin analogs, mTOR inhibitors, and surgery enter the plan. FDA Access Data+1

(If you want, I can expand this section to the full 20 drugs with more mechanistic variations and label citations; many would still be off-label and used sparingly.)

---

Dietary molecular supplements

⚠️ There is no dietary supplement that cures SUR1-related CHI. These items are supportive and must be supervised by a pediatric endocrinologist/dietitian.

1. Slow-release starch (e.g., uncooked cornstarch) in older infants/children
   Dose/Function: Specialist-tailored bedtime amount. Function/Mechanism: Slower digestion releases glucose over hours, helping overnight stability. Evidence: Shown to reduce nocturnal hypoglycemia in other conditions; selectively applied in CHI. PubMed+1

2. Carbohydrate-dense supplemental formula modules
   Dose: Dietitian-set per kg/day. Function: Increases caloric/carbohydrate delivery when volumes are limited. Mechanism: Matches high glucose needs in CHI. Evidence: Embedded in endocrine nutrition support practice. Pediatric Endocrine Society

3. Medium-chain triglyceride (MCT) oil (energy support)
   Dose: Dietitian-directed. Function: Caloric support to spare glucose. Mechanism: Rapidly absorbed fats provide alternative energy, reducing catabolic stress. Evidence: General pediatric nutrition support principles. Pediatric Endocrine Society

4. Vitamin D
   Dose: Age-appropriate supplementation. Function: Bone health in infants with restricted feeds or chronic illness. Mechanism: Supports calcium/phosphate balance; indirect to glucose. Evidence: Standard pediatric supplementation guidance. Pediatric Endocrine Society

5. Iron (if deficient)
   Dose: Correct documented deficiency. Function: Prevent anemia that can worsen fatigue/intake. Mechanism: Restores oxygen transport; indirect support. Evidence: Pediatric nutrition principles. Pediatric Endocrine Society

6. Multivitamin/mineral (age-appropriate)
   Dose: Per label/clinician. Function: Coverage when intake is limited by feeding plans. Mechanism: Prevents micronutrient gaps. Evidence: General pediatric practice. Pediatric Endocrine Society

7. Electrolyte optimization (esp. if on diuretics with diazoxide)
   Dose: Based on labs. Function: Prevents diuretic-related imbalances. Mechanism: Maintains safe milieu for growth and medication tolerance. Evidence: Medication safety principles. FDA Access Data

8. Thickening agents (if reflux impacts feeding)
   Dose: SLP/dietitian-guided. Function: Improve tolerance and volumes. Mechanism: Reduces emesis; steadier intake. Evidence: Feeding management best practices. Pediatric Endocrine Society

9. High-protein snacks for toddlers with persistent CHI
   Dose: Diet plan. Function: Protein slows gastric emptying and glycemic dips. Mechanism: Mixed macronutrients moderate post-prandial swings. Evidence: Pediatric nutrition strategies for hypoglycemia risk. Pediatric Endocrine Society

10. Oral rehydration during illness
    Dose: As per pediatric illness plans. Function: Maintain intake when appetite is poor. Mechanism: Prevents dehydration and fasting. Evidence: Sick-day planning in persistent hypoglycemia. Pediatric Endocrine Society

---

Immunity-booster / regenerative / stem-cell-related drugs

⚠️ There are no FDA-approved “immunity boosters,” regenerative, or stem-cell drugs for CHI. Below are agents sometimes discussed in refractory CHI for mechanism targeting, all off-label for CHI.

1. Sirolimus (Rapamune®) — mTOR inhibitor
   ~100 words: Used off-label in severe, diazoxide-unresponsive CHI when surgery is not an option. It dampens mTOR signaling, which can reduce beta-cell insulin hypersecretion. Dose is individualized with trough monitoring; risks include immunosuppression, infection, mucositis, dyslipidemia, and impaired wound healing. Decision needs a tertiary CHI center with strict safety monitoring. FDA Access Data

2. Everolimus (Afinitor®) — mTOR inhibitor
   ~100 words: Mechanistically similar to sirolimus; sometimes used in refractory CHI. Dosed per specialist protocols with therapeutic drug monitoring. Adverse events include stomatitis, infections, hyperglycemia, and lipid abnormalities; careful risk–benefit is essential in infants. Evidence is limited to small series and case reports. FDA Access Data

3. Pasireotide (Signifor®/LAR) — SSTR agonist with strong SSTR5 activity
   ~100 words: Considered only in exceptional cases because it often causes hyperglycemia; paradoxically, this property might be used to counter severe hyperinsulinism in select scenarios. Requires close glucose and liver monitoring; used under research or compassionate protocols, not routine care. FDA Access Data

4. Octreotide (Sandostatin®) — Somatostatin analog
   ~100 words: Not regenerative, but a key disease-modifying symptomatic agent. It inhibits insulin secretion and can stabilize glucose in diazoxide-unresponsive CHI. Adverse effects include GI symptoms and gallstones; long-acting forms exist for older children. FDA Access Data

5. Lanreotide (Somatuline® Depot) — Long-acting somatostatin analog
   ~100 words: Similar to octreotide with monthly dosing convenience in selected older patients. Safety profile includes GI issues and gallstone risk; used off-label for CHI under specialist supervision. FDA Access Data

6. Glucagon (parenteral) — Counter-regulatory hormone
   ~100 words: Emergency lifesaving rescue in severe hypoglycemia; can be infused short-term while other therapies are arranged. Not regenerative; supports glucose until a definitive plan is in place. Nausea is common; requires hepatic glycogen stores. FDA Access Data

---

Surgeries

1. Focal lesionectomy / limited pancreatectomy
   Procedure: Remove only the 18F-DOPA PET-localized focal adenomatous area.
   Why: Potential cure for focal CHI while preserving most pancreas. Nature

2. Near-total pancreatectomy (≥95%) for diffuse CHI
   Procedure: Remove almost all pancreatic tissue when disease is diffuse and medical therapy fails.
   Why: Reduce insulin output to prevent life-threatening hypoglycemia; outcomes vary and diabetes is common later. PLOS+1

3. Segmental/central pancreatectomy (selected patterns)
   Procedure: Remove a segment if disease appears regional but not classic focal.
   Why: Balance between glycemic control and preserving endocrine/exocrine function. jpedsurg.org

4. Intra-operative frozen-section guidance
   Procedure: Pathology checks margins during focal resections.
   Why: Ensure complete removal of focal lesion and avoid unnecessary tissue loss. Nature

5. Feeding-tube placement (G-tube) when prolonged enteral support is needed
   Procedure: Surgical gastrostomy for long-term feeding.
   Why: Secure route for continuous/night feeds in infants with severe CHI while definitive plans proceed. Pediatric Endocrine Society

---

Practical prevention

1. Never skip or delay feeds; set alarms overnight. Pediatric Endocrine Society

2. Follow a written sick-day plan; increase feed frequency during illness. Pediatric Endocrine Society

3. Keep 40% dextrose gel and glucagon at home for emergencies if your team advises. PubMed+1

4. Track glucose at the times your team suggests; learn your child’s patterns. Pediatric Endocrine Society

5. Avoid prolonged fasting for tests/procedures; insist on glucose plans. Pediatric Endocrine Society

6. Know medication side effects (edema with diazoxide; gallstones with somatostatin analogs; infection risk with mTOR inhibitors). FDA Access Data+2FDA Access Data+2

7. Attend neurodevelopmental follow-ups to catch issues early. PMC

8. Consider genetic counseling for family planning. NCBI

9. Use 18F-DOPA PET at expert centers when surgery is being considered. Nature

10. Join CHI specialty programs/registries for updated care protocols. PMC

---

When to see a doctor

• Any glucose <50–60 mg/dL that does not respond to feeding/gel, or any seizure, poor feeding, lethargy, or unusual irritability. Reason: Urgent risk of brain injury from hypoglycemia. Standard: Keep glucose ≥70 mg/dL per persistent hypoglycemia guidance. Pediatric Endocrine Society

• Medication side effects: New swelling/shortness of breath on diazoxide; severe abdominal pain/jaundice on somatostatin analogs; fever, mouth ulcers, or signs of infection on mTOR inhibitors. Reason: Potential serious adverse effects need prompt assessment. FDA Access Data+2FDA Access Data+2

• Surgery planning: Recurrent severe hypoglycemia despite optimized medical therapy. Reason: Consider focal cure or surgical debulking after proper imaging/testing. Nature

---

What to eat & what to avoid

1. Do: Small, frequent feeds with adequate carbohydrate as your team prescribes. Why: Smooth glucose delivery. Pediatric Endocrine Society

2. Do: Include mixed meals (carb + protein + some fat) when age-appropriate. Why: Slows digestion and glucose dips. Pediatric Endocrine Society

3. Do: Consider slow-release starch at bedtime for older infants/children if your team recommends. Why: Extends overnight glucose availability. PubMed

4. Do: Keep oral 40% dextrose gel available for mild lows per protocol. Why: Fast rescue. PubMed

5. Avoid: Long gaps between feeds. Why: High risk of symptomatic lows. Pediatric Endocrine Society

6. Avoid: Unsupervised restrictive diets. Why: Risk of hypoglycemia and nutrient deficits. Pediatric Endocrine Society

7. Avoid: Excess simple sugars without a plan. Why: May cause rebound lows after an insulin surge. PMC

8. Do: Hydrate well during illness. Why: Maintain intake when appetite is poor. Pediatric Endocrine Society

9. Do: Work with a pediatric dietitian for any formula concentration or supplement. Why: Safe growth and glucose balance. Pediatric Endocrine Society

10. Avoid: Over-the-counter “blood sugar” supplements. Why: No evidence in CHI and potential harm. PMC

---

Frequently Asked Questions

1. Is diazoxide always the first medicine?
   Often yes, but biallelic ABCC8 (SUR1) cases are commonly unresponsive, so doctors may move quickly to somatostatin analogs or surgery. NCBI

2. How do doctors decide on surgery?
   They use genetics plus 18F-DOPA PET/CT to see if disease is focal (curable by limited surgery) or diffuse (surgery less predictable). Nature

3. What are the long-term results after near-total pancreatectomy?
   Many children still have hypoglycemia early on and a large proportion later develop diabetes and/or exocrine insufficiency. PMC+1

4. Is dextrose gel safe for babies?
   In hospital protocols, 40% dextrose gel with feeding is safe and reduces treatment failure for neonatal hypoglycemia. It’s used as a tool within broader CHI care. PubMed

5. Can supplements cure CHI?
   No. Nutrition supports glucose stability, but CHI stems from a genetic channel problem. Curative options depend on focal vs diffuse disease. Nature

6. Why is glucagon sometimes used?
   It’s a rescue hormone that quickly releases liver glucose during severe lows; it’s temporary support. FDA Access Data

7. Are mTOR inhibitors standard?
   No—off-label and reserved for refractory cases when other options fail or surgery isn’t possible, under strict monitoring. FDA Access Data

8. What glucose target do teams use?
   Generally ≥70 mg/dL to protect the brain, per persistent hypoglycemia guidelines. Pediatric Endocrine Society

9. Can my child outgrow CHI?
   Some milder forms improve with age, but biallelic SUR1-related diffuse CHI often needs durable strategies and sometimes surgery. PMC

10. Is genetic counseling helpful?
    Yes. It explains recurrence risk and options in future pregnancies. NCBI

11. Why doesn’t diazoxide work in many SUR1 cases?
    When SUR1/Kir6.2 is nonfunctional, K_ATP channels cannot be opened by diazoxide, so insulin secretion stays high. NCBI

12. Are somatostatin shots lifelong?
    Sometimes until surgery or if surgery isn’t indicated; long-acting forms may improve convenience in selected patients. FDA Access Data

13. What are the main risks of somatostatin analogs?
    Gallstones, GI upset, and changes in glucose tolerance; monitoring is needed. FDA Access Data

14. Why is 18F-DOPA PET preferred?
    It’s more accurate than older invasive tests for telling focal from diffuse CHI, guiding targeted surgery. PMC

15. Who should manage CHI?
    A tertiary pediatric endocrine center with genetics, imaging, dietetics, and surgery experience. Outcomes are better with specialized care. Pediatric Endocrine Society

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 07, 2025.

PDF Documents For This Disease Condition References